Literature DB >> 28336122

Familial acute necrotizing encephalopathy with RANBP2 mutation: The first report in Northeast Asia.

Yun-Jeong Lee1, Su-Kyeong Hwang1, So Mi Lee2, Soonhak Kwon3.   

Abstract

BACKGROUND: Acute necrotizing encephalopathy (ANE) is a rare but rapidly progressing encephalopathy following a febrile illness, commonly a viral infection. It is characterized by the features of acute encephalopathy such as seizure, alteration of consciousness, and symmetric involvement of the bilateral thalamus on neuroimaging tests. Although most ANE cases have occurred sporadically, familial or recurrent ANE has been reported in Caucasian patients, with genetic susceptibility to ANE noted in some patients due to a RANBP2 mutation. We report the cases of two Korean siblings with typical ANE and RANBP2 mutation. CASE REPORT: A 2year-old Korean girl presented with prolonged seizures and encephalopathy after two days of febrile illness. Brain computed tomography (CT) showed diffuse brain swelling and low attenuation in the bilateral thalamus. Two months later, her younger sister presented with lethargy and flurries of seizures after a Mycoplasma pneumoniae infection. Brain magnetic resonance imaging scan (MRI) showed a characteristic involvement of the bilateral thalamus, suggesting ANE. Although they received intravenous steroids and immunoglobulin, the older child died; her sister remained in a coma. Both were diagnosed with familial ANE after identifying a common missense mutation in RANBP2 (c.1754C>T: p.Thr585Met) in the younger sister and their father.
CONCLUSIONS: This report is the first case of familial ANE in Northeast Asia identifying a RANBP2 mutation with poor outcome. Due to rapidly deterioration and recurrent nature of familial ANE, genetic test of RANBP2 mutation should be considered for early diagnosis. Further studies are needed to elucidate the nature of ANE.
Copyright © 2017 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute necrotizing encephalopathy; Familial; RANBP2

Mesh:

Substances:

Year:  2017        PMID: 28336122      PMCID: PMC7127085          DOI: 10.1016/j.braindev.2017.02.005

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


Introduction

Acute necrotizing encephalopathy (ANE) is a rare but rapidly progressing encephalopathy, characterized by seizures and rapid alteration of consciousness, which may progress to coma within days after the onset of febrile infection such as influenza A or parainfluenza, without direct invasion of the central nervous system [1]. Neuroimaging typically shows multiple symmetric brain lesions affecting the thalamus and the brainstem, periventricular white matter, and cerebellum [1]. Most cases are sporadic; however, several cases of familial or recurrent ANE were reported recently in North America and Europe [2], [3], [4]. Patients with mutations in the RANBP2 gene (OMIM601181) have been identified; the gene encodes the nuclear pore component of Ran binding protein 2, causing genetic susceptibility to ANE [2], [3], [4]. Herein, we report the first case of siblings with familial ANE due to RANBP2 mutation from Northeast Asia.

Case reports

Case 1

A previously healthy 2-year-old girl was transferred to our emergency room due to recurrent vomiting and a generalized tonic–clonic seizure after 2 days of cough and fever. She was born at term with uneventful ante- and perinatal periods. Her immunizations were up to date according to the Korean immunization schedule. Seven hours after the first seizure, she developed repetitive seizures and unresponsiveness and became comatose. She was admitted to the intensive care unit with hypotension and respiratory compromise. Laboratory findings, including liver function tests and ammonia levels, were normal. Cerebrospinal fluid (CSF) analysis was normal except for an elevated protein level (protein: 523 mg/dl, glucose: 93 mg/dl). The patient was empirically started on vancomycin, cefotaxime, and acyclovir to treat possible meningoencephalitis. Computed tomography (CT) revealed low attenuation in the bilateral thalamus and diffuse effacement of the sulci and lateral ventricles, indicating diffuse cerebral edema (Fig. 1 ). Despite treatment in intensive care and immunosuppressive therapy including intravenous methylprednisolone (30 mg/kg/day for 2 days) and immunoglobulin (1 g/kg/day for 2 days), the patient died 2 days after the onset of initial neurological symptoms. Results of polymerase chain reaction (PCR) for respiratory viruses (parainfluenza, influenza, corona virus, rhinovirus, respiratory syncytial virus, bocavirus, and enterovirus) and herpes simplex viruses in the CSF as well as the results from cultures for bacteria in the CSF, serum, and urine were all negative.
Fig. 1

Brain CT of Case 1. Axial (A) and coronal (B) non-contrast CT shows low attenuation in the bilateral thalamus (arrowhead) and diffuse effacement of the sulci and lateral ventricles, indicating diffuse cerebral edema.

Brain CT of Case 1. Axial (A) and coronal (B) non-contrast CT shows low attenuation in the bilateral thalamus (arrowhead) and diffuse effacement of the sulci and lateral ventricles, indicating diffuse cerebral edema.

Case 2

Two months after the death of the patient in case 1, her sibling, a 12-month-old girl, presented with 2 days of fever, vomiting, and a seizure. Initial examination revealed that the child was alert without focal neurologic signs. Laboratory findings were within normal ranges except for positive test for Mycoplasma pneumoniae IgM antibody (14 AU/ml, negative test <10 AU/ml). Chest X-ray revealed perihilar infiltration indicating pneumonia. In the next 4 h, she became lethargic and unresponsive. CSF analysis did not show pleocytosis but an elevated protein level (protein: 264 mg/dl, glucose: 63 mg/dl). Brain magnetic resonance imaging (MRI) revealed T2 hyperintensities in the bilateral thalamus, external/extreme capsule, brainstem, and cerebral and cerebellar white matter (Fig. 2 ). Antibiotics and antiviral agents were administered, followed by intravenous methylprednisolone (30 mg/kg/day for 5 days) and immunoglobulin (1 g/kg/day for 2 days). Despite the aggressive immunotherapy, she remained in deep coma with continuous respiratory support.
Fig. 2

Brain MRI of Case 2. Fluid attenuated inversion recovery images (A, B) reveal hyperintense signal changes in the bilateral thalamus, external/extreme capsule, brainstem tegmentum, and mammillary bodies as well as multifocal foci in cerebral and cerebellar white matter. Diffusion-weighted images (C, D) show diffusion restrictions in the bilateral thalamus and mammillary bodies.

Brain MRI of Case 2. Fluid attenuated inversion recovery images (A, B) reveal hyperintense signal changes in the bilateral thalamus, external/extreme capsule, brainstem tegmentum, and mammillary bodies as well as multifocal foci in cerebral and cerebellar white matter. Diffusion-weighted images (C, D) show diffusion restrictions in the bilateral thalamus and mammillary bodies. The characteristic MRI findings and family history of encephalopathy indicated familial ANE. We performed next generation sequencing followed by direct sequencing of entire coding regions of the RANBP2 gene for the younger sister. She was diagnosed as ANE1 after identifying a heterozygous missense mutation in the RANBP2 gene (c.1754C > T: p.Thr585Met) (Fig. 3 ). The genetic testing result were negative for her mother but the father showed the same mutation, but was asymptomatic. We diagnosed familial ANE based on clinical features and the family mutations.
Fig. 3

Sequencing electropherograms of RANBP2-specific cDNA reveals a c.1754C > T mutation in the patient from case 2 and the father, but not in the mother. We could not perform genetic analysis on the patient from case 1 (deceased).

Sequencing electropherograms of RANBP2-specific cDNA reveals a c.1754C > T mutation in the patient from case 2 and the father, but not in the mother. We could not perform genetic analysis on the patient from case 1 (deceased).

Discussion

Although we understand ANE from a wider perspective [5], here we report the first familial case of two Korean siblings with ANE with a mutation in RANBP2 (c.1754C > T: p.Thr585Met). Since the first description of ANE in 1995 [1], numerous cases of sporadic ANE have been reported. In 2009, Neilson et al. reported multiple affected family members with acute necrotizing encephalopathy [2]. They identified a recurrent missense mutation (c.1754C > T: p.Thr585Met, c.1958C > T: p.Thr653Ile, c.1966A > G: p.Ile656Val) in the RANBP2 gene in a large multigenerational family with autosomal-dominant ANE and concluded this gene mutation predisposes patients to increased susceptibility to familial ANE with an estimated 40% penetrance [2]. Hence, the sporadic form is referred to as ANE, and the familial/recurrent form with RANBP2 mutation is referred to as ANE1 with various clinico-radiological presentations [4]. However, the pathogenic mechanism of RANBP2 mutation for ANE1 remains unclear. Several authors believe that RANBP2 may be a critical modulator of neuronal activity, glucose catabolism, and energy homeostasis [2], [6]. However, there are case reports of familial and recurrent ANE without RANBP2 mutation, suggesting a heterogeneous genetic contribution to ANE [7]. Till date, 61 patients with RANBP2 mutation-positive ANE have been reported in American and European populations [4], [8] but only one case of recurrent ANE with RANBP2 mutation has been reported from Asia (an Indian child) [9]. Previous reports suggested that patients with ANE1 presented MRI changes of ANE with additional regions in any of the following structures: medial temporal lobe, insular cortex, claustrum, external capsule, amygdala, hippocampus, mammillary bodies, and spinal cord [2], [4]. Similarly, our case 2 patient presented neuroimaging findings with bilateral thalamus and the external capsule and mammillary bodies. These findings may also suggest ANE1. Although our patients received intravenous steroids and immunoglobulin within 24 h after onset, the outcomes were poor. According to previous outcome data of 30 patients with ANE1, 4(13%) died, 17(57%) had neurological or cognitive sequelae, and 9(30%) made full recovery [4]. Immunomodulation therapy has been suggested for the management of ANE1 in children, in which a fetal course has been frequently reported [10]. We report the first Northeast Asian case of siblings with familial ANE diagnosed by characteristic MRI results and RANBP2 mutation. Typically poor outcome of ANE1 in cases of familial childhood encephalopathy shows that early diagnosis of ANE1 is important for prompt treatment and to prevent rapid deterioration of neurological health. Further studies with a larger group is necessary to identify the nature and the proper management of ANE1.
  10 in total

Review 1.  Untreated recurrent acute necrotising encephalopathy associated with RANBP2 mutation, and normal outcome in a Caucasian boy.

Authors:  Ne-Ron Loh; Donald Barry Appleton
Journal:  Eur J Pediatr       Date:  2010-05-15       Impact factor: 3.183

2.  Variable clinical course in acute necrotizing encephalopathy and identification of a novel RANBP2 mutation.

Authors:  Katharina Sell; Katja Storch; Gabriele Hahn; Min Ae Lee-Kirsch; Georgia Ramantani; Sandra Jackson; Derek Neilson; Maja von der Hagen; Ute Hehr; Martin Smitka
Journal:  Brain Dev       Date:  2016-02-26       Impact factor: 1.961

3.  Familial acute necrotizing encephalopathy without RANBP2 mutation: Poor outcome.

Authors:  Naoko Nishimura; Yoshihisa Higuchi; Nobusuke Kimura; Fumihito Nozaki; Tomohiro Kumada; Ai Hoshino; Makiko Saitoh; Masashi Mizuguchi
Journal:  Pediatr Int       Date:  2016-11       Impact factor: 1.524

Review 4.  RANBP2 mutation and acute necrotizing encephalopathy: 2 cases and a literature review of the expanding clinico-radiological phenotype.

Authors:  Rahul R Singh; Sagar Sedani; Ming Lim; Evangeline Wassmer; Michael Absoud
Journal:  Eur J Paediatr Neurol       Date:  2014-12-09       Impact factor: 3.140

5.  Clinical spectrum and prognostic factors of acute necrotizing encephalopathy in children.

Authors:  Hye-Eun Seo; Su-Kyeong Hwang; Byung Ho Choe; Min-Hyun Cho; Sung-Pa Park; Soonhak Kwon
Journal:  J Korean Med Sci       Date:  2010-02-17       Impact factor: 2.153

6.  Infection-triggered familial or recurrent cases of acute necrotizing encephalopathy caused by mutations in a component of the nuclear pore, RANBP2.

Authors:  Derek E Neilson; Mark D Adams; Caitlin M D Orr; Deborah K Schelling; Robert M Eiben; Douglas S Kerr; Jane Anderson; Alexander G Bassuk; Ann M Bye; Anne-Marie Childs; Antonia Clarke; Yanick J Crow; Maja Di Rocco; Christian Dohna-Schwake; Gregor Dueckers; Alfonso E Fasano; Artemis D Gika; Dimitris Gionnis; Mark P Gorman; Padraic J Grattan-Smith; Annette Hackenberg; Alice Kuster; Markus G Lentschig; Eduardo Lopez-Laso; Elysa J Marco; Sotiria Mastroyianni; Julie Perrier; Thomas Schmitt-Mechelke; Serenella Servidei; Angeliki Skardoutsou; Peter Uldall; Marjo S van der Knaap; Karrie C Goglin; David L Tefft; Cristin Aubin; Philip de Jager; David Hafler; Matthew L Warman
Journal:  Am J Hum Genet       Date:  2009-01       Impact factor: 11.025

7.  Acute necrotising encephalopathy of childhood: a new syndrome presenting with multifocal, symmetric brain lesions.

Authors:  M Mizuguchi; J Abe; K Mikkaichi; S Noma; K Yoshida; T Yamanaka; S Kamoshita
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-05       Impact factor: 10.154

8.  Immunomodulatory therapy in recurrent acute necrotizing encephalopathy ANE1: is it useful?

Authors:  Laura Bergamino; Valeria Capra; Roberta Biancheri; Andrea Rossi; Angela Tacchella; Linda Ambrosini; Masashi Mizuguchi; Makiko Saitoh; Maria Grazia Marazzi
Journal:  Brain Dev       Date:  2011-09-25       Impact factor: 1.961

9.  RanBP2 modulates Cox11 and hexokinase I activities and haploinsufficiency of RanBP2 causes deficits in glucose metabolism.

Authors:  Azamat Aslanukov; Reshma Bhowmick; Mallikarjuna Guruju; John Oswald; Dorit Raz; Ronald A Bush; Paul A Sieving; Xinrong Lu; Cheryl B Bock; Paulo A Ferreira
Journal:  PLoS Genet       Date:  2006-09-01       Impact factor: 5.917

10.  RANBP2 mutation in an Indian child with recurrent acute necrotizing encephalopathy.

Authors:  Vishal Sondhi; Biswaroop Chakrabarty; Atin Kumar; Sudha Kohli; Renu Saxena; I C Verma; Sheffali Gulati
Journal:  Brain Dev       Date:  2016-08-30       Impact factor: 1.961

  10 in total
  4 in total

1.  Case Report of RANBP2 Mutation and Familial Acute Necrotizing Encephalopathy.

Authors:  Mohamad Paktinat; Kamran Hessami; Soroor Inaloo; Hamid Nemati; Pegah Katibeh; Marzieh Nejabat; Mohammad Hassan Darabi; Ali Hosseini Bereshneh
Journal:  Int J Pediatr       Date:  2021-03-13

Review 2.  Moonlighting nuclear pore proteins: tissue-specific nucleoporin function in health and disease.

Authors:  Ramona Jühlen; Birthe Fahrenkrog
Journal:  Histochem Cell Biol       Date:  2018-10-25       Impact factor: 4.304

3.  Radiological manifestation of familial acute necrotizing encephalopathy with RANBP2 mutation in a Far-East Asian family: Case report.

Authors:  Yu-Jung Park; Jae-Yeon Hwang; Yong-Woo Kim; Yun-Jin Lee; Ara Ko
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817

Review 4.  Roles of Nucleoporin RanBP2/Nup358 in Acute Necrotizing Encephalopathy Type 1 (ANE1) and Viral Infection.

Authors:  Jing Jiang; Yifan E Wang; Alexander F Palazzo; Qingtang Shen
Journal:  Int J Mol Sci       Date:  2022-03-24       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.